













doi:10.101Prolonged Chronic Graft-versus-Host Disease is a Risk
Factor for Thyroid Failure in Long-Term Survivors After
Matched Sibling Donor Stem Cell Transplantation for
Hematologic Malignancies
Bipin N. Savani,1,2 Eleftheria K. Koklanaris,1 Quan Le,1 Aarthi Shenoy,1
Stacey Goodman,2 A. J. Barrett1We studied thyroid function in 81 long-term survivors of allogeneic stem cell transplantation (allo-SCT), with
a median follow-up of 84 months (range, 45 to 166 months). Median age at transplantation was 35 years
(range, 6 to 66). Seventy-two of the patients received a total body irradiation (TBI)–containing conditioning
regimen (n5 23, 12 Gy; n5 49, 13 Gy). Twenty-one of the patients (25.9%) had subclinical hypothyroidism,
and 9 (11.1%) developed overt hypothyroidism at a median of 28 months (range, 3 to 78 months) after
allo-SCT. Multivariate logistic regression analysis demonstrated that prolonged immunosuppressive therapy
(IST) was significantly associated with subclinical hypothyroidism (odds ratio [OR]5 3.8) and overt hypothy-
roidism (OR 5 2.6). Antithyroglobulin and thyroid peroxidase antibody were detected in 12 of 60 patients
tested (20%). No correlation was found between the occurrence of thyroid antibodies and hypothyroidism
(P 5 .13) or chronic graft-versus-host disease (cGVHD) (P 5 .55). In conclusion, thyroid dysfunction is
relatively common after allo-SCTand is more likely to occur in patients receiving prolonged IST for cGVHD;
however, thyroid dysfunction does not appear to be related to an antibody-mediated autoimmune process.
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transplantationINTRODUCTION develop compensated hypothyroidism [6-8].Time to on-Nearly 90% of patients alive 2 years after allogenic
stem cell transplantation (allo-SCT) will become long
term survivors [1], shifting the focus of care from cure
of the original disease to the identification and treatment
of delayed and long-term complications that may affect
quality of life [2-4]. Thyroid failure (both overt and sub-
clinical) is a recognized long-term complication after
allo-SCT that can affect quality of life and predispose
to cardiac and metabolic complications [5]. Approxi-
mately 15% of surviving patients are reported to develop
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6/j.bbmt.2008.11.032set of hypothyroidism after allo-SCT is reported to vary
between 1 year and 10 years [6-8]. Thyroid failure has
been linked to total body irradiation (TBI), but also has
been noted after non-TBI conditioning regimens [7,8].
As transplantation centers increasingly use non-TBI
conditioning (with inclusion of older adults), it is becom-
ing more important to define risk factors for thyroid
dysfunction other than the conditioning regimen. Al-
though a few studies have linked thyroid dysfunction
with chronic graft-versus-host disease (cGVHD), no
consistent link has been demonstrated; furthermore, a re-
lationship among antithyroid antibodies, cGVHD, and
thyroid dysfunction has not been clearly established [9].
In this work, we studied thyroid function in pa-
tients surviving more than 3 years posttransplantation.
Our aim was to identify factors associated with hypo-
thyroidism and to explore the relative contributions
of conditioning regimen, autoantibodies, and cGVHD
to thyroid dysfunction.METHODS
A total of 417 patients with hematologic disorders
underwent allo-SCT from an HLA-identical sibling377
Table 1. Patient Characteristics*
Variable (n 5 81) n (%)








Acute lymphocytic leukemia 3 (3.7)
Chronic myelogenous leukemia 49 (60.5)
Others 4 (4.9)
Stem cell source, n (%)
Bone marrow 15 (18.5)
Peripheral blood stem cells 66 (81.5)
Conditioning regimen, n (%)
TBI–based myeloablative conditioning 72 (90)
Reduced-intensity conditioning 9 (10)
Acute GVHD, n (%)
Grade I-IV 35 (43.2)
Grade II-IV 15 (18.5)
Chronic GVHD, n (%) 66 [limited, 50;
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years posttransplantation were enrolled between April
2005 andOctober 2006 in an institutional reviewboard–
approved long-term evaluation protocol (NHLBI 05-
H-0130; ClinicalTrials.gov identifier NCT00106925).
Of the 111 patients surviving 3 or more years at the
time of study initiation in 2005, 84 patients gavewritten
informed consent according to principles outlined in
the Declaration of Helsinki. Thyroid function tests
were performed in 81 of these patients. Transplanta-
tion conditioning consisted mainly of TBI (12 to 13.6
Gy) and cyclophosphamide (Cy; with and without flu-
darabine [Flu]) (n 5 72) or reduced-intensity condi-
tioning (RIC) with Flu and Cy (n 5 9). All patients
received cyclosporine (CsA) as GVHD prophylaxis.
Acute GVHD (aGVHD) and cGVHD were graded
based onpublished criteria [10,11]. Patient characteris-
tics are summarized in Table 1.extensive, 16] (81.5)
Prolonged IST (> 3 years), n (%) 14 (17)
Mortality beyond 3-year follow-up, n (%) 2 (2.5)
Hypothyroidism (time to hypothyroidism,
median and range), n (%)
All cases (28 months; 3 to 78 months) 30 (37)
Subclinical (20 months; 3 to 38 months) 21 (25.9)
Overt (32 months; 9 to 78 months) 9 (11.1)
Total patients on treatment, n (%) 20 (24.7)
Positive antithyroid antibodies (n 5 60), n (%) 12 (20)
GVHD indicates graft-versus-host disease; TBI, total body irradiation;
IST, immunosuppressive therapy.
*Follow-up period, median of 84 months (range, 25 to 166 months).Thyroid Function Tests and Definitions
Thyroid-stimulating hormone (TSH), thyroxine
(T4), and triiodothyronine (T3) levels were measured
before transplantation and then at 3months, 6 months,
and annually after transplantation. Earlier and more
frequent measurements were made when clinically
indicated. In the last 60 patients studied, antithyroid
antibodies (antithyroglobulin and thyroid peroxidase
antibody) also were measured.
Subclinical hypothyroidismwas defined as elevated
TSH with normal T4 and T3 levels in asymptomatic
patients, with overt hypothyroidism defined as elevated
TSH with low T4 and/or T3 levels with or without
clinical features. In each patient hypothyroidism was
defined as subclinical or overt, whichever occurred first
in this analysis.Statistical Analysis
Clinical and transplantation characteristics were
used to evaluate risk factors for hypothyroidism. The
variables included in the analysis are listed in Table
2. In univariate analyses, c2 or Fisher’s exact tests
were used for categorical variables, and the Mann–
Whitney U-test was used for continuous variables.
Summary statistics (eg, proportions, means, standard
deviations, 95% confidence intervals, medians, and
ranges) were used to describe the patient characteris-
tics, pretransplantation variables, and posttransplanta-
tion outcomes. Kaplan–Meier curves were used to
display the distributions of events among subgroups
of patients. Logistic regression was used for multivar-
iate analysis of associated variables. Statistical signifi-
cance was accepted at P\ .05. All data analyses were
performed using SPSS 15 for Windows (SPSS Inc,
Chicago, IL).RESULTS
Table 1 summarizes patient characteristics, and
Table 2 reports the results of univariate analysis of
factors associated with subclinical and overt hypothy-
roidism. Hypothyroidism occurred in 30 patients,
with a cumulative incidence in these 3-year survivors
of 40% 6 5.9% (Figure 1). The median time to onset
of hypothyroidism was 28 months (range, 3 to 78
months), 20 months (range, 3 to 38 months) for the
subclinical form and 32 months (range, 9 to 78
months) for the overt form. Hypothyroidism was
more likely to occur in older patients (Table 2; Fig-
ure 2A) and in patients requiring prolonged immuno-
suppressive therapy (IST) for long-standing cGVHD
(Table 2; Figure 2B, C, D).
To further explore the relationships among
cGVHD, prolonged IST, and hypothyroidism, we
analyzed the cGVHD group separately. A total of 52
patients developed cGVHD requiring treatment for
less than 3 years. Of these, 13 (25%) developed hypo-
thyroidism, compared with 11 of 14 patients (78.5%)
with cGVHD persisting beyond 3 years and requiring
IST (P\ .0001). Our data demonstrate no significant
difference in the rate of hypothyroidism (P5 .088) and
positive thyroid antibodies (P 5 .5) between patients
with limited cGVHD and those with extensive
cGVHD. Thus, the duration of cGVHD appears to
Table 2. Factors Associated with Hypothyroidism
Factor (n)
Subclinical Overt Overall
n (%) P value n (%) P value n (%) P value
Age (< vs > median) .526 .484 .557
# median (41) 11 (26.8) 4 (9.7) 15 (36.5)
> median (40) 10 (25) 5 (12.5) 15 (37.5)
Age quartiles .161 .037 .476
First three (61) 18 (29.5) 4 (6.5) 22 (36)
Oldest quartile (20) 3 (15) 5 (25) 8 (40)
Sex .193 .428 .335
Male (47) 10 (21.2) 3 (8.8) 16 (34)
Female (34) 11 (32.3) 6 (12.7) 14 (41.1)
Type of SCT .413 .528 .494
Bone marrow (15) 3 (20) 2 (11.7) 5 (33.3)
Peripheral blood stem cells (66) 18 (27.2) 7 (10.6) 25 (37.8)
TBI* .573 .261 .442
Yes (72) 19 (26.3) 7 (9.7) 26 (36.1)
No (9) 2 (22.2) 2 (22.2) 4 (44.4)
Acute GVHD .184 .214 .494
Grade 0-I (66) 19 (28.7) 6 (9) 25 (37.8
Grade II-IV (15) 2 (13.3) 3 (20) 5 (33.3)
Chronic GVHD .192 .432 .365
Yes (66) 15 (23) 8 (12.1) 23 (34.8)
No (15) 6 (40) 1 (6.7) 7 (46.6)
Prolonged IST† .031 .044 .001
Yes (14) 7 (50) 4 (28.5) 11 (78.5)
No (67) 14 (20.8) 5 (7.4) 19 (28.3)
SCT indicated stem cell transplantation; TBI, total body irradiation; GVHD, graft-versus-host disease; IST, immunosuppressive therapy.
*No significant difference in patients with a TBI dose of 12 Gy and those with a TBI dose of 13.6 Gy.
†IST beyond 3 years posttransplantation.
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of cGVHD. These data must be interpreted with
caution, because only a small number of patients devel-
oped extensive cGVHD.More than half of the patients
with subclinical hypothyroidism (11 of 21) eventually
required thyroid replacement therapy. Multivariate
logistic regression analysis showed that prolonged
IST was independently associated with both overt
and subclinical hypothyroidism (overt: odds ratio
[OR] 5 2.6, 95% confidence interval [CI] 5 1.1 to
21.4, P 5 .04; subclinical: OR 5 3.8, 95% CI 5 1.2
to 14.4, P5 .03). In the subgroup of 11 patients receiv-
ing prolonged IST initially diagnosed with subclinical
hypothyroidism, all became symptomatic and required
thyroid replacement therapy.Relationships among Antithyroid Antibodies,
cGVHD, and Hypothyroidism
Sixty of the 81 patients were tested for antithyroid
antibodies (antithyroglobulin and thyroid peroxidase
antibody), and 12 (20%) were positive for either or
both antibodies. But no significant association was
found between the presence of antithyroid antibodies
and hypothyroidism; antibodies were found in 7 of
24 patients (29%) with hypothyroidism and in 5 of
36 (14%) without hypothyroidism (P5 .13). Similarly,
no association was found between cGVHD and posi-
tive antithyroid antibodies; 10 of 48 patients (20.8%)
with a history of cGVHD were positive, compared
with 2 of 12 (16.6%) without cGVHD (P5 .55) (Table2). To further explore the relationship between pro-
longed IST and antithyroid antibodies, we analyzed
patients with history of cGVHD separately. Four of
12 patients (33%) requiring prolonged IST (. 3 years)
for cGVHD were positive for antithyroid antibodies,
compared with 6 of 36 (17%) with cGVHD of less
than 3 years duration (P5 .202). These results further
confirm a lack of association between antithyroid anti-
bodies with cGVHD requiring prolonged IST.DISCUSSION
Our findings demonstrate that hypothyroidism is
a significant late complication in long-term allo-SCT
survivors, occurring in almost 40% of patients surviv-
ing 3 or more years after transplantation SCT. In con-
trast to previous studies [7,12-15], we found prolonged
IST for ongoing cGVHD (both overt and subclinical
hypothyroidism) and increasing age (overt hypothy-
roidism) as the only risk factors for hypothyroidism
in patients followed up for a median of 7 years.
Previous studies of thyroid function tests in chil-
dren and adolescents receiving allo-SCT showed that
younger children (aged\ 10 years) were more likely
to have thyroid dysfunction compared with older chil-
dren [6,16]. Our studies do not contradict these obser-
vations, because it included only 2 patients aged\ 10
years at the time of transplantation; most of the pa-
tients were adults, including 21 patients aged . 44
years. The patients aged 44 to 66 years had










Figure 1. Cumulative incidence of hypothyroidism.
380 Biol Blood Marrow Transplant 15:377-381, 2009B. N. Savani et al.a significantly higher rate of overt hypothyroidism in
univariate analysis; however, the effect of age was con-
founded by the fact that 8 of 14 patients in this older
cohort received prolonged IST for cGVHD.
Although no significant impact of conditioning reg-
imen intensity (Table 2) was found, we cannot exclude
a possible contribution of TBI to the development of
hypothyroidism, because only aminority of our patients
received a nonmyeloablative conditioning regimen.Our
data suggest that the thyroid may be susceptible to al-
loimmune attack associated with prolonged cGVHD;
however, we could not confirm that cGVHD per se is
a provocative factor for thyroid damage, because we
found no relationship among hypothyroidism, antithy-
roid antibodies, and cGVHD. It may be that thyroid
damage is simply T cell–mediated or that prolongedA
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Figure 2. Associations between age and overt hypothyroidism (A), prolon
subclinical (D) hypothyroidism.IST per se damages the thyroid gland. Importantly, we
found that all patients with subclinical hypothyroidism
requiring prolonged IST developed symptomatic hypo-
thyroidism and required replacement therapy. This
might indicate the need for early replacement therapy,
especially for those in this patient groupwho are seen in-
frequently at our clinic. The debate continues on
whether or not to treat patients with subclinical hypo-
thyroidism [6,17,18]. Initially, we and others [6] did
not treat subclinical hypothyroidism, in contrast to
other investigators [18]. An important rationale for
treating subclinical hypothyroidism is to decrease the
risk of thyroid adenoma and carcinoma [19,20] and, in
young patients, to prevent growth failure and delayed
development. SCT recipients are at increased risk of de-
veloping second malignancies [21,22]. A European
Group for Blood and Marrow Transplantation study
found that thyroid cancer was the most common sec-
ondary cancer, with a standardized incidence ratio ap-
proaching 50 in long-term survivors after SCT.
Similar to our findings, the risk factors for developing
secondary cancer were extensive cGVHD and IST for
cGVHD. To date, none of our patients has developed
thyroid cancer or hyperthyroidism.
The development of thyroid dysfunction after allo-
SCT has been linked to an autoimmune process;
however, the true incidence of clinically significant au-
toimmune thyroid dysfunction after allo-SCT remains
unknown. It has been reported that thyroid damage af-
ter allo-SCT, causing transient subclinical hypothy-
roidism and low-titer thyroid antibodies, may beB
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Biol Blood Marrow Transplant 15:377-381, 2009 381Thyroid Dysfunction after Allogeneic Stem Cell Transplantationcommon [23]. In small case series, autoimmune thy-
roid dysfunction has been described in up to 3% of
allo-SCT survivors [9,24]. But we found no correlation
between the development of thyroid autoantibodies
and hypothyroidism. Thus, although an alloimmune
response may contribute to thyroid dysfunction after
allo-SCT, it does not appear to be mediated through
the classical autoantibody pathway. Further investiga-
tion is needed to determine how the cGVHD process
affects the thyroid.ACKNOWLEDGMENTS
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